The Half-Cycle Correction Revisited

Naimark, David; Kabboul, Nader N.; Krahn, Murray

doi:10.1177/0272989x13501558

Cited by 31 publications

(33 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We refer the reader to Naimark et al. ()'s study for alternative approaches to the half‐cycle correction method. We calculate r t ( s t , DN , o ) as follows:

\begin{matrix} r_{t} false(s_{t}, DN, o false) & = 0.5 \times P (alive in period t | current state is s_{t}) \\ + 0.25 \times P (dies in period t | current state is s_{t}), \\ o \in {scriptO}_{DN}, s_{t} \in \bar{S}, t \in T . \end{matrix}

That is, the immediate rewards for DN action are independent of the observation made and

r_{t} false(s_{t}, DN false) = r_{t} false(s_{t}, DN, {italicDN}^{-} false) = r_{t} false(s_{t}, DN, {italicDN}^{+} false), \forall s_{t} \in \bar{S}, \forall t \in T .

On the other hand, depending on the observation made, M action leads to some disutilities that decrement the QALY of the patient.…”

Section: Problem Formulationmentioning

confidence: 99%

Analysis of Mammography Screening Policies under Resource Constraints

Çevik

Ayer

Alagöz

et al. 2018

Production and Operations Management

View full text Add to dashboard Cite

Breast cancer, the leading cause of cancer death for women, can be detected at earlier stages through mammography screening. Therefore, most developed countries implemented population‐based mammography screening programs. However, cost of mammography and limited resources in terms of number of trained personnel and diagnostic machines prevent mammography screening to be adopted by many other countries. In fact, even in resource‐rich countries, there is a growing concern about cost of mammography screening. In this study, we investigate the optimal allocation of limited mammography resources to screen a population. We propose a constrained partially observable Markov decision process (CPOMDP) model that maximizes total expected quality‐adjusted life years of the patients when they are allowed only a limited number of mammography screenings. We use a variable resolution grid‐based approximation scheme to convert the CPOMDP model into a mixed‐integer linear program and conduct several numerical experiments using breast cancer epidemiology data. We observe that as mammography screening capacity decreases, patients in the 40–49 age group should be given the least priority with respect to screening. We further find that efficient allocation of available resources between patients with different risk levels leads to significant quality‐adjusted life year gains, especially for the patients with higher breast cancer risk.

show abstract

“…We refer the reader to Naimark et al. ()'s study for alternative approaches to the half‐cycle correction method. We calculate r t ( s t , DN , o ) as follows:

\begin{matrix} r_{t} false(s_{t}, DN, o false) & = 0.5 \times P (alive in period t | current state is s_{t}) \\ + 0.25 \times P (dies in period t | current state is s_{t}), \\ o \in {scriptO}_{DN}, s_{t} \in \bar{S}, t \in T . \end{matrix}

That is, the immediate rewards for DN action are independent of the observation made and

r_{t} false(s_{t}, DN false) = r_{t} false(s_{t}, DN, {italicDN}^{-} false) = r_{t} false(s_{t}, DN, {italicDN}^{+} false), \forall s_{t} \in \bar{S}, \forall t \in T .

On the other hand, depending on the observation made, M action leads to some disutilities that decrement the QALY of the patient.…”

Section: Problem Formulationmentioning

confidence: 99%

Analysis of Mammography Screening Policies under Resource Constraints

Çevik

Ayer

Alagöz

et al. 2018

Production and Operations Management

View full text Add to dashboard Cite

show abstract

“…The model used monthly cycles. No half-cycle correction was applied because the cycle length was deemed sufficiently short compared to the length of the time horizon [24][25][26].…”

Section: Treatment Sequencesmentioning

confidence: 99%

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

Schweikert¹,

Malmberg²,

Åkerborg

et al. 2020

PharmacoEconomics Open

View full text Add to dashboard Cite

Background Interleukin-17A (IL-17A) antagonists are a recent innovation for treating psoriatic arthritis (PsA). There are currently no cost-effectiveness analyses (CEAs) comparing the IL-17A antagonists ixekizumab and secukinumab in PsA from a UK perspective. Objective We conducted a CEA from the UK National Health Service perspective to compare ixekizumab versus secukinumab in patients with PsA and concomitant moderate-to-severe plaque psoriasis. Methods A Markov model was developed based on the widely accepted York model. In biologic disease-modifying antirheumatic drug (bDMARD)-naïve patients, ixekizumab → ustekinumab → best supportive care (BSC) was compared with secukinumab → ustekinumab → BSC. For bDMARD-experienced patients, ixekizumab → BSC was compared with secukinumab → BSC. At the end of the bDMARD trial period, Psoriatic Arthritis Response Criteria (PsARC) responders continued to receive the bDMARD in the continuous treatment period. PsARC nonresponders and patients who ceased continuous treatment transitioned to the trial period of the next treatment. Results Ixekizumab was less costly and provided more quality-adjusted life-years (QALYs) than secukinumab in bDMARDnaïve and-experienced patients based on list prices, although cost savings and QALY gains were small to modest. In bDMARD-naïve patients, total costs were £155,455 compared with £155,530 for secukinumab (year 2017 values). Total QALYs were 8.127 versus 7.989. In bDMARD-experienced patients, the corresponding values were £140,051 versus £140,264 for total costs and 3.996 versus 3.875 for total QALYs. Conclusion Ixekizumab provided more QALYs at a marginally lower cost than secukinumab, and the results were most sensitive to changes in drug costs. Other factors, such as patient preferences for the number of injections and confidential price discounts, may be important considerations in clinical decision-making.

show abstract

“…The cycle length of the model was 6 months. The cycle tree method was used for half-cycle correction [12].…”

Section: Decision Modelingmentioning

confidence: 99%

Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada

et al. 2016

View full text Add to dashboard Cite

Background. Management of low-grade oral dysplasias (LGDs) is complicated, as only a small percentage of lesions will progress to invasive disease. The current standard of care requires patients to undergo regular monitoring of their lesions, with intervention occurring as a response to meaningful clinical changes. Recent improvements in molecular technologies and understanding of the biology of LGDs may allow clinicians to manage lesions based on their genome-guided risk. Methods. We used a decision-analytic Markov model to estimate the cost-effectiveness of risk-stratified care using a genomic assay. In the experimental arm, patients with LGDs were managed according to their risk profile using the assay, with low- and intermediate-risk patients given longer screening intervals and high-risk patients immediately treated with surgery. Patients in the comparator arm had standard care (biannual follow-up appointments at an oral cancer clinic). Incremental costs and outcomes in life-years gained (LYG) and quality-adjusted life-years (QALY) were calculated based on the results in each arm. Results. The mean cost of assay-guided management was $8,123 (95% confidence interval [CI] $2,973 to $23,062 in 2013 Canadian dollars) less than the cost of standard care. This difference was driven largely by reductions in resource use among people who did not develop cancer. Mean incremental effectiveness was 0.18 LYG (95% CI 0.08 to 0.39) or 0.64 QALY (95% CI 0.46 to 0.89). Sensitivity analysis suggests that these findings are robust to both expected and extreme variation in all parameter values. Conclusion. Use of the assay-guided management strategy costs less and is more effective than standard management of LGDs.

show abstract

The Half-Cycle Correction Revisited

Cited by 31 publications

References 5 publications

Analysis of Mammography Screening Policies under Resource Constraints

Analysis of Mammography Screening Policies under Resource Constraints

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada

Contact Info

Product

Resources

About